We pioneer Labeling Excellence for the digital era.
Alnexia exists to standardize and strengthen labeling requirements across the global healthcare industry — establishing ourselves as the definitive end-to-end partner for integrated labeling excellence.
Born from the FHIR transition.
The shift from static PDF leaflets to structured, machine-readable healthcare data is the most consequential regulatory change in a generation. The EU Pharmaceutical Legislation Reform — politically agreed in late 2025 — moved ePI from a pilot to a central pillar of how medicines are managed in Europe.
Alnexia was built specifically to help Marketing Authorisation Holders cross that bridge. We combine regulatory expertise with FHIR engineering rigour, partnering with industry leaders to ensure every ePI we ship is compliant, validated and submitted on time.
The world we want
A world where every medicine's information stays connected and in sync — never late, wrong or hard to trust — where regulatory teams meet every labeling mandate without losing sleep, and every patient is empowered to understand the medicine in their hands.
A nexus — the point of connection
True to its name, Alnexia is the end-to-end labeling partner that connects authoring, validation and submission into one trusted flow. We turn the pressure of a global regulatory deadline into the confidence of a validated, inspection-ready submission — and empower patients with digitalised labeling that is clear, accessible and easy to use.
Four operating principles
Standards-first
We build on EMA, HL7 FHIR, SPOR and IDMP — never on private silos.
Patient-led
Faster updates, accessible content, integrated records. Patients first.
Interoperable
Every artifact is structured, validated and ready for the network effect.
Audit-ready
Published scores, immutable fix logs, validator evidence — proof beats promises.